These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2663321)

  • 21. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase.
    Joubert PH; Foukaridis GN; Bopape ML
    Eur J Clin Pharmacol; 1987; 31(6):723-4. PubMed ID: 3549325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HbA(1c) and glycemic profile, basal- and post-treatment with Miglitol, in an area with a Mediterranean diet.
    Faure E; Pallardo LF; Mesa J; Puig-Domingo M; García-Mayor R; Benito P; Ravella R; Artés M; López JS;
    Diabetes Care; 2002 Oct; 25(10):1896-8. PubMed ID: 12351510
    [No Abstract]   [Full Text] [Related]  

  • 23. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
    Scott LJ; Spencer CM
    Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha-glucosidase inhibition and timing of preprandial insulin in patients with insulin-dependent diabetes mellitus (IDDM).
    Kennedy FP; Gerich JE
    Diabetes Res Clin Pract; 1988 Apr; 4(4):309-12. PubMed ID: 3286168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.
    Sels JP; Nauta JJ; Menheere PP; Wolffenbuttel BH; Nieuwenhuijzen Kruseman AC
    Br J Clin Pharmacol; 1996 Oct; 42(4):503-6. PubMed ID: 8904624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics.
    Standl E; Schernthaner G; Rybka J; Hanefeld M; Raptis SA; Naditch L
    Diabetes Res Clin Pract; 2001 Mar; 51(3):205-13. PubMed ID: 11269893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
    Van Gaal L; Maislos M; Schernthaner G; Rybka J; Segal P
    Diabetes Obes Metab; 2001 Oct; 3(5):326-31. PubMed ID: 11703422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
    Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
    Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
    Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Miglitol, a new alpha-glucosidase inhibitor.
    Sels JP; Huijberts MS; Wolffenbuttel BH
    Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The acute effects of glucosidase inhibition on post-meal glucose increments in insulin-dependent diabetics.
    Wing J; Kalk WJ; Berzin M; Diamond TH; Griffiths RF; Smit AM; Osler CE
    S Afr Med J; 1990 Mar; 77(6):286-8. PubMed ID: 2180090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses.
    Requejo F; Uttenthal LO; Bloom SR
    Diabet Med; 1990 Jul; 7(6):515-20. PubMed ID: 2163805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man.
    Lembcke B; Fölsch UR; Gatzemeier W; Ebert R; Siegel E; Creutzfeldt W
    Pharmacology; 1991; 43(6):318-28. PubMed ID: 1784628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
    Campbell LK; Baker DE; Campbell RK
    Ann Pharmacother; 2000 Nov; 34(11):1291-301. PubMed ID: 11098345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients.
    Schnack C; Röggla G; Luger A; Schernthaner G
    Eur J Clin Pharmacol; 1986; 30(4):417-9. PubMed ID: 3527720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors].
    Blicklé JF; Andres E; Brogard JM
    Rev Med Interne; 1999 Aug; 20 Suppl 3():379s-383s. PubMed ID: 10480189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099).
    Russell JC; Graham SE; Dolphin PJ
    Metabolism; 1999 Jun; 48(6):701-6. PubMed ID: 10381143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
    Axen KV; Li X; Sclafani A
    Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.
    Sels JP; Kingma PJ; Wolffenbuttel BH; Menheere PP; Branolte JH; Nieuwenhuijzen Kruseman AC
    Neth J Med; 1994 Jun; 44(6):198-201. PubMed ID: 8052342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.